Dunsire Deborah 4

What Happened Deborah Dunsire, a director of Ultragenyx Pharmaceutical Inc. (RARE), received equity awards on May 14, 2026: 7,751 restricted stock units (RSUs) and 14,058 shares reported as a derivative (an option). Both grants were recorded at $0.00 (i.e., granted, not purchased), for a combined total of 21,809 shares. Per the filing footnotes, the RSUs and the option vest in full on the earlier of the company's next Annual Meeting of Stockholders or May 14, 2027.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (covers the May 14 transaction).
• Price: $0.00 per share (award/grant). Transaction code: A = Award/Grant.
• Shares granted: 7,751 RSUs + 14,058 derivative/option = 21,809 total.
• Vesting: Both awards vest in full on the earlier of the next Annual Meeting or May 14, 2027 (see footnotes F1 and F2).
• Shares owned after the transaction: not specified in the provided filing.
• No indication in the provided filing of a 10b5‑1 plan, cashless exercise, or tax‑withholding sale.

Context These grants appear to be routine director compensation (time‑based RSUs and an option) rather than an open‑market purchase or sale. Awards like these do not immediately change market exposure because they vest later; they generally reflect standard pay practices for board members rather than a direct trading signal.